Investment
Features
FeesSafety
Academy
More
Pluang+

Cambria Gold Mines inks $150K marketing deal with Maximus for project promotion

Market News
19 Oct 2026
GlobeNewsWire
View Source
Neutral
Cambria Gold Mines inks $150K marketing deal with Maximus for project promotion

Cambria Gold Mines has signed a four-month online marketing agreement with Maximus Strategic Consulting, paying C$150,000 to promote its Premier Gold and Red Mountain projects. Maximus will feature Cambria's news releases in its weekly newsletter and produce a promotional video distributed via PinnacleDigest.com. This move aims to increase visibility for Cambria's mining projects in British Columbia and Washington State, pending TSX Venture Exchange approval. The partnership does not involve equity exchange, and Maximus holds no shares in Cambria.

Cambria Gold Mines marketing agreement news provides context for Basic Materials sector data on Pluang. For readers following Basic Materials, here is Pluang's market snapshot as of Oct 20, 2026 03:42 WIB: Out of 83 priced US stocks, 31 rose and 51 fell. Notable movers include CLF at USD 14.14 with a +16.67% change and a typical hold time of 0 days, ALM at USD 8.81 down -10.38%, and STLD at USD 229.00 down -4.80%.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
1 hour ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
1 hour ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
2 hours ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
3 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App